Form 13-F position report

ARROWHEAD PHARMACEUTICALS INC

Reported by M28 Capital Management LP

ARWR CUSIP 04280A100 Manager CIK 0001807489

Reported 67,400 shares, unchanged from the prior quarter.

Reported value -2.9%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 1.24% This manager · Q4 2024
Shares 67,400 Quarter-end amount reported
Reported value $1,267,120 Fair value at quarter end
Consecutive quarters held 9 Through Q4 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-12-31 5836584
2023-03-31 1711960
2023-06-30 2403484
2023-09-30 1811038
2023-12-31 2062440
2024-03-31 1927640
2024-06-30 1751726
2024-09-30 1305538
2024-12-31 1267120
2025-03-31 858676
2025-06-30 1064920
2025-09-30 2324626
2025-12-31 4474686
2026-03-31 2310558
2026-06-30 3003725

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for ARROWHEAD PHARMACEUTICALS INC held by M28 Capital Management LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Unchanged 36,851 0 (0.0%) 6.37% $3,003,725 2026-08-13
Q1 2026 Reduced 36,851 -30,549 (-45.3%) 4.29% $2,310,558 2026-05-14
Q4 2025 Unchanged 67,400 0 (0.0%) 3.25% $4,474,686 2026-02-13
Q3 2025 Unchanged 67,400 0 (0.0%) 3.42% $2,324,626 2025-11-13
Q2 2025 Unchanged 67,400 0 (0.0%) 1.82% $1,064,920 2025-08-13
Q1 2025 Unchanged 67,400 0 (0.0%) 1.18% $858,676 2025-05-14
Q4 2024 Unchanged 67,400 0 (0.0%) 1.24% $1,267,120 2025-02-13
Q3 2024 Unchanged 67,400 0 (0.0%) 1.43% $1,305,538 2024-11-12
Q2 2024 Unchanged 67,400 0 (0.0%) 2.27% $1,751,726 2024-08-13
Q1 2024 Unchanged 67,400 0 (0.0%) 1.42% $1,927,640 2024-05-14
Q4 2023 Unchanged 67,400 0 (0.0%) 1.71% $2,062,440 2024-02-12
Q3 2023 Unchanged 67,400 0 (0.0%) 2.08% $1,811,038 2023-11-13
Q2 2023 Unchanged 67,400 0 (0.0%) 3.18% $2,403,484 2023-08-11
Q1 2023 Reduced 67,400 -76,500 (-53.2%) 1.94% $1,711,960 2023-05-12
Q4 2022 New 143,900 +143,900 (0.0%) 5.56% $5,836,584 2023-02-10

Who else reported the position

313 managers reported ARROWHEAD PHARMACEUTICALS INC for Q4 2024.

Managers reporting ARROWHEAD PHARMACEUTICALS INC in Q4 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 16,178,000 +342,088 < 0.01% $304,146,400 2 qtrs
VANGUARD GROUP INC Reduced 12,184,289 -44,766 < 0.01% $229,064,633 35 qtrs
Avoro Capital Advisors LLC Added 11,111,111 +2,222,223 2.95% $208,888,887 7 qtrs
STATE STREET CORPORATION Reduced 6,016,227 -338,104 < 0.01% $113,105,068 36 qtrs
Slate Path Capital LP Added 5,232,000 +347,000 1.78% $98,361,600 5 qtrs
FMR LLC Reduced 5,101,083 -966,486 < 0.01% $95,900,355 26 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 2,954,947 -9,172 < 0.01% $55,565,848 35 qtrs
Siren L L C Added 2,901,681 +442,903 2.41% $54,551,603 2 qtrs
T Rowe Price Investment Management Inc Reduced 2,507,296 -1,067,277 0.03% $47,138,000 4 qtrs
NORGES BANK Added 2,054,364 +9,702 < 0.01% $38,622,043 22 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2024
Filed
February 13, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
67,400
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.